Homepage Top Section2

The fast-track application included top-line data from the double-blind randomised Phase II clinical trial, which showed efficacy on the modified Unified Multiple System Atrophy Rating Scale (UMSARS)I alongside

These patents have a base patent term extending until June 2040. This is contingent upon the alteration due to any delays in the prosecution process and extension to

Last month, PCI signed a deal to acquire Ajinomoto Althea, a subsidiary of Japan-based Ajinomoto. This acquisition is part of PCI’s investment strategy to enhance its manufacturing capabilities

This fixed-dose combo of Perjeta (pertuzumab) and Herceptin (trastuzumab), delivered via SC injection along with intravenous chemotherapy, offers a subcutaneous (SC) treatment option for human epidermal growth factor

According to the company, Zevaskyn is the first and only autologous cell-based gene therapy. The FDA’s decision is supported by the outcomes from the pivotal randomised intrapatient-controlled multi-centre

This status is conferred by the European Commission following a positive opinion from the EMA Committee for orphan medicinal products and offers several benefits, including market exclusivity and

The acquisition enables Apnimed to advance the therapy through its joint venture (JV) with Japanese pharma company, Shionogi & Co. Desitin Arzneimittel will receive an upfront, future milestone

This initiative aims to harness biological and clinical insights, identify new drug targets, and create therapeutics for the oncology sector. The collaboration will leverage de-identified oncology data of

This recommendation facilitates treating the activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in patients aged 12 years and above. The oral therapy is now accessible and funded in